PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ErbB2 and p53 – Important Antibodies for Cancer Research - The overexpression of the c-erbB-2 (HER-2/neu) gene product, a 185 kDa transmembrane receptor protein, is associated with cell transformation and tumorigenesis.
ErbB2 and p53 – Important Antibodies for Cancer Research

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2006/11/06 - The overexpression of the c-erbB-2 (HER-2/neu) gene product, a 185 kDa transmembrane receptor protein, is associated with cell transformation and tumorigenesis..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

It shares homology with the epidermal growth factor receptor and intrinsic tyrosine kinase activity, HER-2/neu gene is amplified and overexpressed in 25-30% of human breast and ovarian cancers. Overexpression of the protein, as determined by immunohistochemistry, is associated with poor prognosis (1,2).

One of the most important mammalian cell cycle checkpoint proteins is the tumor suppressor protein, p53. In normal, undamaged cells, p53 is rapidly degraded. However, when cells are treated with DNA damage-inducing agents, there is a transient accumulation of p53 protein and it is activated as a transcription factor. In several types of human cancers, p53 is mutated (3,4). Human p53 protein has been shown to be phosphorylated at several N-terminal and C-terminal sites that affect site-specific DNA binding and interaction with other cellular and viral proteins in vitro (5-10). Phosphorylation at serines 6, 9, 15, 20, 33, 37 occur after cells are exposed either to ionizing radiation or to UV light (11,12). Serines 6 and 15 were demonstrated to be one of the strongest and earliest phosphorylated sites in response to DNA damage-induced posttranslational modifications (13, 14).

With a focus on providing targeted solutions for cancer research, AnaSpec, a leading provider of integrated proteomics solutions, offers a highly specific selection of c-erbB-2 (HER-2/ neu) and p53 polyclonal antibodies. AnaSpec’s collection of p53 antibody products includes both phosphospecific and non-phosphospecific solutions.

• Anti-C-erbB-2

• Anti-P53 (pSer6), phospho-specific

• Anti-P53 (Paired6), non-phospho-specific

• Anti-P53 (pSer9), phospho-specific

• Anti-P53 (Paired9), non-phospho-specific

• Anti-P53 (pSer15), phospho-specific

• Anti-P53 (Paired15), non-phospho-specific

References:

1. Hudson, LG. et al. J. Biol. Chem. 265, 2389 (1990).
2. Reese, DM and DJ. Slamon. Stem Cells 15, 1 (1997).
3. Brown, JM et al (1999) Cancer Res. 59:1391-1399
4. Albrechtsen, N et al (1999) Oncogene 18:7706-7717
5. Wang, L. et al (2001) J. Biol Chem. 276, 43604 (2001).
6. Xirodimas, D et al (2001) Oncogene 20 (36):4972-83
7. Backlund, MG et al (2001) Cancer Res. 61(17): 6577-82
8. Sakaguchi, K et al (2000) J. Biol. Chem. 275:9278-83
9. Banin, S et al (1998) Science 281: 1674-1677
10. Canman, CE et al (1998) Science 281: 1677-1679
11. Burns, TF et al J. cell Physiol. 181: 231-239
12. Oren, M et al (1999) J. Biol. Chem 274:36031-36034
13. Lakin, ND et al (1999) Oncogene 18: 7644-7655
14. Higashimoto, Y et al (2000) J Biol Chem. 275:23199-23203

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


ErbB2 and p53 – Important Antibodies for Cancer Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Research Most Recent Related Newswires:

DSM-Niaga Ready for Commercial Scale Production of 100%-recyclable Carpets
DSM Dyneema Introduces Whole New Level of Cut Protection with Black Dyneema® Diamond Technology
DSM Presents Sustainable and Healthy Dairy Solutions At FoodTech 2016
Frost & Sullivan Highlights GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
DSM to Present its Latest Advances in Skin Biochemistry At IFSCC Conference
DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant
DSM Dyneema Successfully Defends Key Patent Against Competitor Challenge
DSM Expands its Automotive Electronics Portfolio with High-flow Akulon PA66
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions
BD Announces New Software Release for Pyxis Enterprise Solution
DSM Opens its Asia Pacific Personal Care Technical & Application Center in Shanghai

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  NAKIVO, Inc.





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)